April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Inhibition of cyclophilin D by cyclosporin A promotes retinal ganglion cell survival by preventing mitochondrial alteration in ischemic injury
Author Affiliations & Notes
  • Won-Kyu Ju
    Hamilton Glaucoma Center/Ophthalmology, Univ of California San Diego, La Jolla, CA
  • Sang Yeop Kim
    Hamilton Glaucoma Center/Ophthalmology, Univ of California San Diego, La Jolla, CA
  • Myoung Sup Sim
    Hamilton Glaucoma Center/Ophthalmology, Univ of California San Diego, La Jolla, CA
  • Keun-Young Kim
    Neuroscience, Univ of California San Diego, La Jolla, CA
  • Robert N Weinreb
    Hamilton Glaucoma Center/Ophthalmology, Univ of California San Diego, La Jolla, CA
  • Larry A Wheeler
    Biological Sciences, Allergan, Inc., Irvine, CA
  • Footnotes
    Commercial Relationships Won-Kyu Ju, Allergan, Inc (F); Sang Yeop Kim, None; Myoung Sup Sim, None; Keun-Young Kim, None; Robert Weinreb, Allergan, Inc (C); Larry Wheeler, Allergan, Inc (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 2431. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Won-Kyu Ju, Sang Yeop Kim, Myoung Sup Sim, Keun-Young Kim, Robert N Weinreb, Larry A Wheeler; Inhibition of cyclophilin D by cyclosporin A promotes retinal ganglion cell survival by preventing mitochondrial alteration in ischemic injury. Invest. Ophthalmol. Vis. Sci. 2014;55(13):2431.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Cyclosporin A (CsA) inhibits the opening of the mitochondrial permeability transition pore (MPTP) by interacting with cyclophilin D (CypD) and ameliorates neuronal cell death in the central nervous system against ischemic injury. However, the molecular mechanisms underlying CypD/MPTP-mediated cell death in ischemic retinal injury remain unknown.

Methods: Transient retinal ischemia was induced by acute IOP elevation. Either vehicle or CsA treatment daily for 1 day before the induction of transient retinal ischemia and then continued vehicle or CsA (5mg/kg/day) treatment daily for 2 weeks. Retinal ganglion cell (RGC) survival was measured by immunohistochemstry for Brn3a. Apoptotic pathway was assessed by TUNEL staining and Western blot for cleaved caspase-3, Bcl-xL and phosphorylated Bad (pBad). Mitochondrial DNA (mtDNA) alteration were assessed by Western blot for mitochondrial transcription factor A (Tfam) and measurement for mtDNA content.

Results: We observed the first direct evidence that CsA prevented the upregulation of CypD protein expression at 12h and promoted RGC survival against ischemic injury. Moreover, CsA blocked apoptotic cell death by decreasing cleaved caspase-3 protein expression in ischemic retina. Of interest, while the expression level of Bcl-xL protein did not show a significant change in ischemic retina treated with vehicle or CsA at 12 h, ischemic damage induced the reduction of Bcl-xL immunoreactivity in RGCs. More importantly, CsA preserved Bcl-xL immunoreactivity in RGCs of ischemic retina. In parallel, acute IOP elevation significantly increased phosphorylated Bad at Ser112 (pBad) protein expression in ischemic retina at 12 h. However, CsA significantly preserved pBad protein expression in ischemic retina. Finally, acute IOP elevation significantly increased Tfam protein expression in ischemic retina at 12 h. However, CsA significantly preserved Tfam protein expression in ischemic retina. Studies on mtDNA content in ischemic retina showed that there were no statistically significant differences in mtDNA content among control and ischemic groups treated with vehicle or CsA.

Conclusions: These results provide evidence that the activation of CypD-mediated MPTP opening is associated with apoptotic pathway and mitochondrial alteration in RGC death of ischemic retinal injury.

Keywords: 600 mitochondria • 615 neuroprotection • 572 ischemia  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×